Coccidioidomycosis is a fungal infection picked up by breathing in spores from dry soil in parts of the southwestern US and Latin America. Many people with coccidioidomycosis have no symptoms, but some develop flu‑like illness with fever, cough, chest pain, fatigue, and rash. Most cases of coccidioidomycosis get better over weeks to months, while severe or prolonged disease can occur in people with weak immune systems, during pregnancy, in older adults, and in certain ethnic groups. Treatment ranges from rest and pain relief to antifungal medicines like fluconazole, and hospital care for severe lung or widespread infection. Death is uncommon but can occur in severe disseminated coccidioidomycosis, so early evaluation and follow‑up matter.
Overview
CoccidioidomycosisSymptoms
Coccidioidomycosis (Valley fever) often feels like the flu: fever, dry cough, chest pain, fatigue, headache, and joint or muscle aches. A red, painful shin rash and night sweats can appear. Many have mild illness; severe breathing problems are less common.
Outlook and prognosis
Most people with coccidioidomycosis recover fully with rest and, when needed, antifungal treatment. Symptoms often improve over weeks to months, though fatigue can linger. A small group—especially those with weakened immunity, pregnancy, or certain ethnic backgrounds—may need longer care.
Causes and risk factors
Coccidioidomycosis results from inhaling Coccidioides spores released from dry, disturbed soil in endemic areas. Risk rises with dust exposure, construction work, farming, and dust storms. Severe disease is likelier with pregnancy, weakened immunity, diabetes, older age, or certain ancestries.
Genetic influences
Genetics play a limited role in coccidioidomycosis risk and severity. Certain inherited immune variants, including those affecting interferon-gamma and STAT1 pathways, can raise susceptibility and complications. People of African or Filipino ancestry may face higher risk of disseminated disease.
Diagnosis
Doctors diagnose Coccidioidomycosis using your symptoms, exposure history, and region. They confirm it with blood tests for antibodies, sometimes sputum or tissue tests, and chest imaging; the diagnosis of Coccidioidomycosis may be repeated over time to track changes.
Treatment and drugs
Coccidioidomycosis treatment depends on severity, overall health, and immune status. Many mild lung infections are monitored with rest and symptom care, while moderate to severe disease usually needs antifungal medicines like fluconazole or itraconazole for months. Complicated or widespread cases may require amphotericin B, longer therapy, and specialist follow‑up.
Symptoms
Many people notice what feels like a lingering flu—tiredness, cough, and aches that don’t quite go away. Early symptoms of coccidioidomycosis often overlap with a cold or seasonal flu, which can make it easy to miss at first. Symptoms vary from person to person and can change over time. Most people improve over weeks to a few months, but a smaller number develop more serious problems that need medical care.
A low to moderate fever is common and may come with chills. Fevers can come and go for days to weeks as your immune system fights the fungus.
The cough is often dry at first. Chest discomfort or a sharp pain can show up when taking a deep breath or coughing. With coccidioidomycosis, the cough can linger longer than a typical cold.
Many feel wiped out, even after plenty of rest. This deep tiredness can make work, school, or exercise harder for a while.
Waking up sweaty at night is a frequent complaint. These sweats often come in waves alongside fever.
How people usually first notice Coccidioidomycosis?
Many people first notice coccidioidomycosis, often called Valley fever, after a few weeks of dry cough, fever, tiredness, and chest discomfort that began days to weeks after being in dusty, arid areas of the southwestern United States or parts of Latin America. Some develop a red, tender rash on the legs or trunk and joint aches, which can prompt a clinic visit when the “flu” doesn’t improve as expected. For many, the first signs of coccidioidomycosis are flu-like symptoms that linger longer than usual, especially after travel or dust exposure.
Types of Coccidioidomycosis
Coccidioidomycosis has a few well-recognized clinical patterns that range from a mild lung infection to widespread disease. These types help explain why early symptoms of coccidioidomycosis can look like a common cold in some, yet become more severe in others. Not everyone will experience every type. Clinicians often describe them in these categories:
Primary pulmonary
This is the most common form, affecting the lungs after breathing in the fungus. Many people have mild flu-like illness with cough, fever, and fatigue, while some feel no symptoms at all. Chest pain and shortness of breath can develop if inflammation is stronger.
Pulmonary chronic
Symptoms last longer than a few weeks and can resemble long-lasting pneumonia. People may notice persistent cough, weight loss, night sweats, and tiredness. Lung nodules or cavities may form and are usually found on imaging.
Disseminated disease
The infection spreads beyond the lungs through the bloodstream. Skin, bones, joints, and the central nervous system can be involved, leading to painful lesions, swollen joints, or headaches. Meningitis is the most serious form and needs long-term treatment.
Cutaneous localized
Skin involvement occurs close to the entry point or from nearby spread. People may see tender red bumps, ulcers, or draining sores. These usually occur with or after lung symptoms but can also appear on their own.
Silent nodules
Small lung nodules are found incidentally on a chest scan without active symptoms. Most remain stable and do not cause trouble. Doctors monitor these to be sure they are not something else.
What genetics can tell you about symptoms
Most people with coccidioidomycosis don’t have gene-linked symptoms, but certain HLA types and variants affecting interferon-γ or STAT1 can weaken immune signaling, raising the risk of severe lung disease, fever, and fatigue. Variants in IL-12 or CARD9 may tilt symptoms toward chronic pneumonia or widespread infection.
Causes and risk factors
Coccidioidomycosis happens when you breathe in fungal spores from dusty soil in the U.S. Southwest and nearby parts of the Americas, especially during dust storms. Risk factors for Coccidioidomycosis include living or traveling in these areas and jobs or hobbies that stir up dust, like farming or construction. A weak immune system raises the chance of severe disease, including with HIV, organ transplants, chemotherapy, or long-term steroids. Late pregnancy, older age, and diabetes also increase risk, and people of Filipino or Black ancestry face higher odds of widespread infection. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Coccidioidomycosis (Valley fever) is caught by breathing in tiny fungal spores from dry soil in certain regions, so day-to-day surroundings matter. While many watch for early symptoms of coccidioidomycosis, understanding who is more likely to be exposed or to have severe illness can guide when to seek care. Doctors often group risks into internal (biological) and external (environmental). Below are the environmental exposures and body-based factors that can raise risk.
Living in or traveling to parts of Arizona, California, New Mexico, West Texas, and northern Mexico raises the chance of coccidioidomycosis. Some areas of Central and South America also carry risk. Longer stays in these regions mean more exposure to local dust.
Strong winds can lift contaminated dust high into the air and carry it far. Inhaling that dust during a storm can trigger Valley fever. Visibility may be low, but spore levels can still be high.
Construction, farming, and excavation churn up soil and release spores, increasing coccidioidomycosis risk nearby. Military training and road building can have similar effects. People downwind may also be exposed.
Gusty days increase airborne dust in endemic areas. More dust in the air means more spores available to breathe in.
Genetic risk factors
Inherited traits can influence how your immune system handles coccidioidomycosis, especially whether infection stays in the lungs or spreads. Genetic background does not change the early symptoms of coccidioidomycosis, but it can affect the likelihood of severe or disseminated disease. Risk is not destiny—it varies widely between individuals. Rare single‑gene immune conditions and certain ancestry backgrounds are the clearest genetic links found so far.
Ancestry background: People of African or Filipino ancestry have higher odds of disseminated coccidioidomycosis. This pattern points to inherited differences in immune response. The risk varies within each group and does not mean others are protected.
Inborn immune defects: Rare, inherited immune conditions can make it harder to control the fungus, raising the chance of severe or widespread infection. Many involve the IL‑12/interferon‑gamma pathway, which helps white blood cells coordinate their response. These conditions are uncommon but important when coccidioidomycosis is unusually severe or recurrent.
CARD9 or Dectin‑1 variants: Changes in genes such as CARD9 or Dectin‑1 are linked to serious fungal infections. When present, they may increase susceptibility to disseminated coccidioidomycosis. Genetic counseling may be considered if multiple relatives have severe fungal disease.
Family history: Having a close relative with disseminated coccidioidomycosis suggests shared inherited susceptibility. This does not mean illness is inevitable, but your baseline risk may be higher. Clinicians may consider genetic evaluation when severe disease clusters in a family.
Male sex: Men have higher rates of severe or disseminated disease compared with women. This difference likely reflects genetic and hormonal influences, though specific genes are still being defined. Sex is a fixed risk you cannot change.
Lifestyle risk factors
Certain habits and activities can raise your chance of breathing in the fungus that causes Coccidioidomycosis, especially when soil is disturbed and becomes airborne. The most important lifestyle risk factors for Coccidioidomycosis involve how, where, and when you create or encounter dust. Diet and exercise matter mainly in how they affect your lungs and immune system rather than directly causing infection. The list below focuses on lifestyle risk factors for Coccidioidomycosis and ways those behaviors influence exposure or illness severity.
Work that disturbs soil—such as construction, farming, archaeology, or military training—raises spore inhalation risk. Skipping soil-wetting or other dust-control practices further increases exposure.
Off‑road driving, trail running, mountain biking, and hiking on dry dirt tracks kick up dust you can inhale. Windy conditions or group events on dusty trails amplify the risk.
Digging, landscaping, and leaf blowing aerosolize soil and spores. Doing these tasks without wetting the ground or using a respirator increases exposure.
Visiting regions where the fungus lives and spending time in dusty outdoor settings can be enough to acquire infection. Short, high‑dust activities during a trip carry disproportionate risk.
Risk prevention
Coccidioidomycosis (Valley fever) is picked up by breathing in fungal spores from dusty soil, especially in dry, windy areas of the southwestern United States and parts of the Americas. You can’t avoid every exposure, but practical steps can lower your chances during dust storms, yard work, construction, or travel to high-risk regions. Even if you can’t remove all risks, prevention can reduce their impact. Knowing common triggers and the early symptoms of Coccidioidomycosis helps you act sooner if you’ve been exposed.
Stay indoors during dust storms and high winds in endemic areas. Keep windows closed and use recirculated air in cars.
Wear a well-fitted N95 or FFP2 respirator when you must be in blowing dust or disturbing soil. This barrier can cut the amount of spores you breathe in.
Dampen ground before digging, sweeping, or yard work to keep dust down. Using water to control dust helps reduce exposure to Coccidioidomycosis spores.
Use HEPA filtration or high-efficiency HVAC filters at home and work, especially during dusty periods. Portable HEPA units can lower indoor spore levels in rooms you use most.
Transmission
Coccidioidomycosis (Valley fever) is acquired by breathing in microscopic fungal spores that become airborne when dry soil is disturbed, such as during windstorms, construction, or farming. The fungus lives in the ground in the southwestern United States and parts of Mexico and Central and South America, so living in or traveling to these regions raises the chance of exposure.
Coccidioidomycosis does not spread from person to person, and you can’t catch it through casual contact, sex, or from pets; rare cases have occurred through organ transplantation or laboratory accidents. In short, how Coccidioidomycosis spreads is through the environment—not from people—so limiting dusty air exposure in endemic areas can lower risk.
When to test your genes
Coccidioidomycosis is an acquired infection, so genetic testing isn’t used to diagnose it. Consider testing only if you have a strong family history of severe fungal infections or known immune-system gene variants that raise risk, especially if you live in or travel to endemic regions. Talk with your clinician first.
Diagnosis
Many people first seek care when a stubborn cough, chest pain, or fatigue lingers after time in a dusty, windy area or a recent trip. Doctors usually begin by asking about where you live or traveled, your work or outdoor activities, and how your symptoms changed over time. If you live in or traveled to the US Southwest or parts of Latin America, mention it, as it guides the diagnosis of coccidioidomycosis. The goal is to confirm the cause, check how widespread it is, and choose the right treatment.
Your provider asks about residence or travel in endemic regions and dust exposure from work or outdoor activities. Timing of symptoms after that exposure helps narrow the cause.
The exam looks for fever, rash, tender joints, or lung findings that fit with Valley fever. These clinical features point the workup toward specific tests.
Blood tests check for coccidioidal antibodies (early and later types) and may include confirmatory methods and titers to gauge severity. Early samples can be negative, so repeat testing in 1–3 weeks may be needed.
A chest X-ray or sometimes CT scan looks for pneumonia patterns, nodules, or cavities. Imaging helps assess how the lungs are affected and flags complications that need closer care.
Stages of Coccidioidomycosis
Coccidioidomycosis does not have defined progression stages. The illness can be mild and short-lived in many people, but in some it can linger in the lungs or spread to other parts of the body, so doctors focus on the form and severity rather than fixed stages. Different tests may be suggested to help confirm the diagnosis and check how far the infection has spread, including review of early symptoms of coccidioidomycosis, chest X-rays or CT scans, and blood tests that look for your immune response. Follow-up visits and repeat blood tests over time help monitor recovery or spot complications if symptoms persist.
Outlook and prognosis
Looking ahead can feel daunting, but most people with coccidioidomycosis get better with time—especially when it’s caught early and treated when needed. Many living with coccidioidomycosis have a flu-like illness that eases over weeks to a few months. Some feel tired or short of breath for longer, and a smaller group develops skin, joint, or lung nodules that linger. Early symptoms of coccidioidomycosis can be mild, so people sometimes recover without realizing they had it. Prognosis refers to how a condition tends to change or stabilize over time.
For otherwise healthy adults with lung-only disease, the long‑term outlook is generally good, and most recover fully without antifungal medication. People with weaker immune systems, those who are pregnant (especially in the third trimester), and individuals with certain medical conditions face a higher risk for severe or widespread infection. When the fungus spreads beyond the lungs—most often to the skin, bones, or brain—treatment is longer and may include lifelong antifungal therapy to prevent relapse. Mortality is uncommon in routine lung disease but can be significant with severe pneumonia or meningitis; prompt diagnosis and treatment lower that risk.
Over time, most people with coccidioidomycosis resume normal activities, though some may need a gradual return as cough and fatigue fade. Relapses can happen, but they’re less likely when treatment is completed and follow‑up is consistent. Knowing what to expect can ease some of the worry. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Many people recover fully and return to normal routines after Valley fever, but some live with lasting issues. Long-term effects vary widely, from mild tiredness to chronic lung or nervous system problems. While early symptoms of coccidioidomycosis often fade within weeks, lingering cough, fatigue, or joint pain can persist for months. A small group develop chronic or disseminated disease that may need ongoing follow-up.
Persistent tiredness and low stamina can follow the illness even after other signs resolve. Many find they tire sooner during work, chores, or exercise.
A dry or sometimes phlegmy cough can linger, often with chest discomfort. For some, it flares with colds or heavier activity.
Healed areas can leave small nodules or thin-walled cavities in the lungs. These may show up on scans and occasionally cause shortness of breath or rare coughing of blood.
In a subset, the fungus persists in the lungs, leading to ongoing cough, weight loss, and night sweats. Symptoms can wax and wane over months or years.
How is it to live with Coccidioidomycosis?
Living with coccidioidomycosis—Valley fever—often means a long, frustrating fatigue that lingers after the fever and cough fade, with good days and setbacks that can make work, school, or exercise feel unpredictable. Many people recover fully, but some need months of rest, clinic visits, and antifungal medication, and a smaller group—especially those who are pregnant, have weakened immune systems, or are of certain ancestries at higher risk—may face more serious disease that requires close, ongoing care. Daily life may involve pacing activities, wearing a mask or avoiding dusty outdoor work in endemic areas, and leaning on family or coworkers for help with chores or flexible schedules. For loved ones, understanding that the exhaustion is real—and not a lack of effort—goes a long way, and most find that with time, treatment when needed, and steady support, life returns to a familiar rhythm.
Treatment and drugs
Coccidioidomycosis (Valley fever) treatment depends on how severe your symptoms are and whether the infection is limited to the lungs or has spread. Many people with mild lung disease recover with rest, fluids, and pain/fever reducers, while doctors monitor closely without antifungal drugs. When medicine is needed, first-line antifungals such as fluconazole or itraconazole are commonly used for several months; more serious disease, pregnancy, weakened immunity, or infection that spreads beyond the lungs may call for hospitalization and intravenous amphotericin B before switching to pills. A doctor may adjust your dose to balance benefits and side effects, and treatment can last 3–12 months or longer in complex cases, with periodic blood tests and imaging to track progress. If you notice side effects or symptoms worsening—like persistent fever, chest pain, headaches with stiff neck, or new skin or joint issues—contact your care team promptly.
Non-drug treatment
Alongside medicines, non-drug therapies can ease cough, fatigue, and chest discomfort while your body fights coccidioidomycosis. These approaches focus on rest, lung support, and daily routines that help you recover steadily. They can be especially helpful when early symptoms of coccidioidomycosis—like dry cough and tiredness—make normal activities hard. Not every approach works the same way for everyone, so it’s fine to try a few and see what helps most.
Plan your day with frequent breaks and lighter tasks to match your energy. Overexertion can flare cough and fatigue in coccidioidomycosis. What feels difficult at first can become more manageable with a steady routine.
Sip water and warm liquids to thin mucus and soothe the throat. Aim for balanced meals with enough protein and calories to support recovery.
Slow, deep breathing and gentle coughing techniques can help move mucus and ease chest tightness. A clinician may suggest tools or simple routines to guide your practice in coccidioidomycosis.
Use a cool-mist humidifier or steam from a warm shower to moisten airways and calm cough. Clean devices regularly to prevent mold buildup, and avoid very hot steam to reduce burn risk.
Your genes may have an impact on how drugs work for you
Medicines for coccidioidomycosis, like fluconazole, can be processed faster or slower depending on your genes, which affects how much drug reaches steady levels in your body. Pharmacogenetic testing isn’t routine, but genes may guide dose choices or alternatives if side effects or poor response occur.
Pharmacological treatments
Treatment depends on how severe the infection is and your overall health. Even if early symptoms of coccidioidomycosis are mild, people at higher risk or with persistent illness may need antifungal medication. Not everyone responds to the same medication in the same way. Doctors may change the drug or dose based on response and side effects.
Often the first choice when coccidioidomycosis needs treatment, including for lung disease and meningitis. It is usually taken once daily and often continued for many months, sometimes long-term for meningitis.
Common alternative, especially helpful for bone, joint, or skin involvement in coccidioidomycosis. It works best when taken with food and may require checking drug levels and liver tests.
Used when disease is severe or has not responded to other azoles. It can affect vision or skin sensitivity to sunlight, so monitoring and sun protection are important.
Option for refractory disease or when other azoles are not tolerated. It can be effective for difficult cases and requires checking for drug interactions and liver effects.
Genetic influences
Genetic differences help explain why some people exposed to the Valley fever fungus clear the infection easily while others develop more serious illness. Rare, inherited immune problems that weaken how the body recognizes and fights fungi can increase the chance of widespread (disseminated) coccidioidomycosis. Higher rates of dissemination have been reported in people of African or Filipino ancestry, suggesting a genetic influence, though environment, exposure, and overall health also play important roles. Having a genetic risk is not the same as having the disease itself. Genetic differences don’t usually change early symptoms of coccidioidomycosis, such as cough, fever, or fatigue; they mainly affect the likelihood that the infection spreads beyond the lungs. Because of this, genetic testing isn’t routine for coccidioidomycosis, but in severe, recurrent, or unusual cases—especially when organs outside the lungs are involved—your care team may suggest an immune evaluation or genetic counseling to look for an underlying cause.
Is Coccidioidomycosis genetic?
Genetics play a limited role in coccidioidomycosis risk and severity. Certain inherited immune variants, including those affecting interferon-gamma and STAT1 pathways, can raise susceptibility and complications. People of African or Filipino ancestry may face higher risk of disseminated disease.
Pharmacogenetics—how genetics influence drug effects
Treatment for coccidioidomycosis usually relies on antifungal medicines, and genes can influence how your body handles some of them. Genetic testing can sometimes identify how your body breaks down certain drugs, which helps doctors choose a starting dose and watch more closely for side effects. When applied to Valley fever care, this is sometimes called pharmacogenetic testing in coccidioidomycosis, and it complements—rather than replaces—your treatment plan.
For example, a common gene (often called CYP2C19) can make voriconazole levels higher or lower than expected; too‑high levels raise the risk of vision or nerve side effects, while too‑low levels may lead to treatment not working well. Fluconazole, another common option, is cleared mostly by the kidneys, so gene differences usually play a smaller role in its dosing; kidney function and other medicines matter more. Itraconazole levels tend to vary because of absorption and drug interactions, so checking blood levels is often more useful than genetic testing. Amphotericin B isn’t handled by the same liver pathways, so genetic differences in drug metabolism aren’t known to guide its dosing for coccidioidomycosis.
Interactions with other conditions
People living with HIV, those on chemotherapy or long-term steroids, and organ or stem-cell transplant recipients face a higher risk that Valley fever will spread beyond the lungs or become severe. In pregnancy—especially late in the third trimester and shortly after delivery—Coccidioidomycosis can be more aggressive, so care teams usually watch symptoms closely. A condition may “exacerbate” (make worse) symptoms of another. For example, COPD or asthma can make the cough and breathlessness of coccidioidomycosis feel heavier, and recovery can take longer.
Diabetes is also linked with more complicated infections, while early symptoms of Coccidioidomycosis can look like the flu or pneumonia, which can delay the right diagnosis when another respiratory illness is present. Lung infections such as tuberculosis or bacterial pneumonia may overlap in how they appear on scans and tests, so doctors often run specific fungal tests to sort things out. Interactions vary widely, but telling your clinician about all diagnoses and recent medications helps them tailor monitoring and treatment if Valley fever is part of the picture.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described stubborn coughs and fevers that followed dust storms or long desert journeys. Community stories often described the condition as a “Valley fever,” especially in parts of the southwestern United States and northern Mexico, where digging, farming, and military training stirred up soil. People noticed that sickness often followed after earthmoving or sandstorms, and that newcomers to these regions seemed to get sicker than longtime residents.
First described in the medical literature as a mysterious skin problem in the late 1800s, coccidioidomycosis was soon linked to a fungus found in arid soil. Early doctors saw clusters among construction workers and farm laborers, then later among prisoners building roads, and soldiers training in dry valleys. As public health tracking improved in the mid-20th century, it became clear that inhaling dust carried tiny fungal spores into the lungs, causing anything from a mild flu-like illness to severe disease in some people.
Over time, descriptions became more complete as labs learned to grow the fungus and blood tests were developed to detect past or recent infection. This helped separate coccidioidomycosis from tuberculosis and other lung infections that can look and feel similar. Researchers also recognized patterns: outbreaks after earthquakes and dust storms, and seasonal rises during dry, windy months. They documented that people with weakened immunity, pregnant people, and some ethnic groups faced higher risks for severe forms.
Advances in genetics refined the picture further. Scientists studied the fungus’s two species, Coccidioides immitis and Coccidioides posadasii, and mapped where each tends to live across the Americas. They also explored how human immunity responds, which explains why most infections are mild or silent while a smaller number progress to pneumonia or spread beyond the lungs.
In recent decades, awareness has grown as more people move to or travel through areas where coccidioidomycosis is common. Urban expansion into desert outskirts, climate variability, and larger dust-generating projects have influenced exposure patterns. Public health campaigns emphasized simple protections—like wetting soil before digging and using masks during dusty work—to reduce risk.
Knowing the condition’s history helps explain today’s approach: watch for early symptoms of coccidioidomycosis after dust exposure, test when illness lingers, and tailor care based on severity and individual risk. The story of coccidioidomycosis, from mistaken identity to well-characterized infection, reflects steady progress—careful observation, better tests, and practical prevention shaped by life in dry, windy places.